What we do IOL Chemicals & Pharmaceuticals Ltd is a global leader in manufacturing Active Pharmaceutical Ingredients and specialty chemicals, serving pharmaceutical and industrial markets worldwide. |
Founded in 1,986 |
Market share Largest global producer of Ibuprofen with diversified API portfolio and significant specialty chemicals capacity, holding strong market positions in India and globally. |
Problem solved Provides essential APIs and specialty chemicals enabling production of key medicines and eco-friendly industrial solvents, addressing global pharmaceutical and environmental needs. |
Top clients or who we serve Serves major pharmaceutical companies like Ranbaxy, Dr Reddy's, Cipla, and industries including pharmaceuticals, packaging, paints, adhesives, B2B and B2C markets. |
Key management Rajender Mohan Malla (Chairman), Varinder Gupta (Managing Director), Vikas Gupta (Joint Managing Director), Abhiraj Gupta (Executive Director), Kushal Kumar Rana (Director-Works). |
Our journey and innovations Since 1986, expanded from Acetic Acid production to leading global Ibuprofen manufacturer and diversified API portfolio with advanced R&D and multiple capacity expansions. |
Where we operate Presence in over 40 countries including India, Switzerland, Spain, Middle East, Africa, and Asia, serving global pharmaceutical and chemical markets. |
Top products or what we offer Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, Fenofibrate, Ethyl Acetate, Iso Butyl Benzene, Acetic Anhydride, Paracetamol and other APIs and specialty chemicals. |
Top brands Ibuprofen (#1 globally, fully backward integrated), Ethyl Acetate (leading Indian producer), Paracetamol (new large capacity unit), multiple USFDA and CEP certified APIs. |
Raw materials needed Key raw materials include Glacial Acetic Acid, Benzene derivatives, Chlorinated chemicals, and intermediates for APIs and specialty chemicals. |
Raw materials supplier Sourced from global chemical suppliers with backward integration in intermediates for quality control and cost efficiency. |
Recurring vs cyclical contribution Revenue mix includes stable recurring API supplies with cyclical specialty chemical demand influenced by industrial cycles. |
Our industry position Industry leader in Ibuprofen API globally; strong growth and presence in specialty chemicals; expanding regulated market approvals and exports. |
Financial highlights FY25 revenue ₹2,079 crore, PAT ₹101 crore; strong EBITDA margin around 10.7%; consistent investment in capacity and R&D. |
Geographical revenue split Majority revenue from India (~72%), with significant exports from rest of world, Switzerland, Spain contributing ~28%. |
Order book Order details not disclosed; consistent demand from large pharma clients sustains strong order book. |
Whats driving growth Growth driven by capacity expansions, diversification to high-value APIs, increasing exports, regulatory approvals, and sustainable specialty chemical production. |
Our future plans Expanding API portfolio with new units for Gabapentin, Paracetamol capacity increased; pursuing more global regulatory approvals and sustainable growth. |
Our green promise Committed to zero liquid discharge, carbon neutrality by 2050, REACH certifications, and reducing greenhouse gas emissions with solar energy use. |
Our people and values Over 3000 employees foster innovation and safety with emphasis on diversity, ethics, and robust governance. |
Key challenges ahead Price volatility in chemical inputs, regulatory risks, global supply chain shifts, and maintaining margins amid competitive pressures. |
Interesting facts Only fully backward integrated global Ibuprofen producer; first in Asia with dual technology MCA & Acetyl Chloride plant; extensive CEP and DMF certifications. |
Risks and strategy Mitigates supply risks through backward integration; diversifies product mix geographically; adheres to global quality standards; focuses on sustainable operations. |
